Delving into the microbiome to identify specific organisms that might mediate the protective effect, the authors honed in on a group of 28 Clostridiales. Remarkably, colonization of antibiotic-treated mice with one of these, *Clostridium scindens*, reduced CHIKV infection in the serum and restored type I IFN levels to those detected in vehicle-treated mice. Colonization with *C. scindens* also prevented transmission of the virus back to mosquitoes after exposing them to the blood of treated mice. *C. scindens* encodes an enzyme that converts primary bile acid into secondary bile acids. Oral administration of secondary bile acid to antibiotic-treated mice prior to CHIKV infection resulted in reduced virus titres and restored type I IFN responses. Thus, the microbiome provides antiviral protection through a bile acid–pDC–IFN signalling axis.

Lucy Bird

The authors developed targeted-IP-multiplex-light-absolute-quantitative mass spectrometry (TIMLAQ-MS) to simultaneously measure the dynamics of ITAM phosphorylation of the different TCR signalling subunits in a single measurement. This revealed distinct patterns and kinetics of phosphorylation of the different subunits. In particular, the ITAM of CD3ε had high levels of monophosphorylation, which is known to be associated with the recruitment of inhibitory molecules. Indeed, monophosphorylated CD3ε was found to bind to the inhibitory tyrosine kinase CSK, which is known to downregulate LCK activity. This indicated that CD3ε may allow for negative feedback regulation of TCR signalling.

As CAR T cell therapies can induce excessive cytokine release, the authors tested whether adding CD3ε to current CAR constructs may allow for better-tuned signalling. Using the clinically approved CD19.28Z CAR construct, which contains signalling domains derived from CD28 and CD3ζ, the authors inserted the entire cytoplasmic domain of CD3ε at the membrane-proximal position. They found that cells containing this construct produced significantly lower levels of cytokines upon stimulation than cells with the parent construct. The authors also found that the BRS motif of CD3ζ can recruit p85, the regulatory subunit of PI3 kinase, to promote persistence of CAR T cells. Thus, CD3ε affects CAR signalling via multiple mechanisms.

In a mouse xenograft model of B cell lymphoma, CAR T cells with the CD3ε module showed improved anti-tumour function. Similar results were obtained when CD3ε was inserted into another CAR construct that is currently tested in mesothelin-expressing solid tumours.

Overall, these results indicate that the TCR is a self-restraining signalling complex and that the CD3ε cytoplasmic domain may serve as a useful module to tune CAR T cells for anticancer immunotherapy.

Alexandra Fleming

**COVID-19**

**Preventing escape from neutralizing antibodies**

Convalescent plasma (CP) and monoclonal antibodies (mAbs), two approaches being evaluated for COVID-19 therapy, are vulnerable to antibody-resistance mutations in SARS-CoV-2 that maintain viral fitness. This preprint describes the use of replication-competent chimeric viruses to generate spike protein escape mutants to four CP samples and three mAbs. Viral RNA from resistant cultures was used to identify shared and treatment-specific escape mutations. The mutations identified in this study are currently found at low frequencies in sequencing databases, but this methodology could be used to monitor emerging virus variants and predict their impact on mAb treatments. These findings support the use of combination mAb regimens and the design of vaccines targeting conserved B cell and T cell epitopes to prevent mutational escape.

**ORIGINAL ARTICLE** Weisklum, Y., et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Preprint at bioRxiv https://doi.org/10.1101/2020.07.21.214799 (2020)

**COVID-19**

**IgGs drive COVID-19 myeloid hyperinflammation**

Recent studies have identified an aberrant myeloid cell activation programme in patients with COVID-19. In this preprint, Hoepel et al. elucidate a mechanism by which alveolar macrophages facilitate hyperinflammation. Serum IgGs, in complex with spike protein, from patients with severe COVID-19 were shown to induce a potent pro-inflammatory response in human macrophages through multiple FcγRs, but mainly through FcγRII. Blockade of this pathway using an inhibitor of the kinase SYK counteracted the pathological production of IL-6, IL-1β and TNF. Interestingly, in vitro exposure of endothelial cells to serum IgGs from these patients resulted in loss of barrier integrity and increased coagulopathy. These results improve our understanding of the abnormal myeloid response in COVID-19 and identify a potential therapeutic target.

**ORIGINAL ARTICLE** Hoepel, W., et al. Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses. Preprint at bioRxiv https://doi.org/10.1101/2020.07.11.191409 (2020)

**COVID-19**

**ACE2 is not induced by interferon**

Interferon (IFN) is emerging as a promising therapeutic for COVID-19. Yet it was also proposed that IFN induces transcription of the SARS-CoV-2 entry receptor ACE2, potentially increasing viral infectivity. In this preprint, Onabago et al. show that it is actually a shorter transcript of ACE2, coined dACE2, that was previously detected by RNA sequencing upon exposure to IFN. Expression of dACE2, but not the canonical ACE2, is induced by viral infection as well as treatment with type I, II and III IFNs. dACE2 is also highly expressed in several tumour tissues, owing to an inflamed microenvironment that resembles virus-infected tissues. Importantly, dACE2 cannot bind to the SARS-CoV-2 spike protein receptor-binding domain and lacks carboxypeptidase activity, dispelling concerns that IFN treatment might enhance viral infection.

**ORIGINAL ARTICLE** Onabago, O. et al. Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. Preprint at bioRxiv https://doi.org/10.1101/2020.07.19.210955 (2020)

Matthew Brown, Matthew D. Park and Miriam Saffern

Sinai Immunology Review Project, Icahn School of Medicine at Mount Sinai, New York, NY, USA

e-mail: sinai.immunology@gmail.com

The authors declare no competing interests.